Processing

Please wait...

Settings

Settings

1. WO2020002325 - COMPOUNDS

Publication Number WO/2020/002325
Publication Date 02.01.2020
International Application No. PCT/EP2019/066819
International Filing Date 25.06.2019
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
50
Cyclic peptides containing at least one abnormal peptide link
54
with at least one abnormal peptide link in the ring
60
the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
62
Polymyxins; Related peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12
Cyclic peptides
C07K 7/62 (2006.01)
A61K 38/12 (2006.01)
CPC
A61K 38/12
C07K 7/62
Applicants
  • SPERO THERAPEUTICS, INC. [US/US]; 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139, US
Inventors
  • BROWN, Pamela; GB
  • DAWSON, Michael; GB
  • SIMONOVIC, Mona; GB
  • BOAKES, Steven; GB
  • DUPERCHY, Esther; GB
  • RIVERS, Dean; GB
  • LESTER, Roy; GB
  • COLEMAN, Scott; US
Agents
  • MEWBURN ELLIS LLP; City Tower 40 Basinghall Street London Greater London EC2V 5DE, GB
Priority Data
62/689,60225.06.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS
(FR) COMPOSÉS
Abstract
(EN)
The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: formula (I) wherein -R15 is a group: formula (II) and -R16 is hydrogen; -R17 is hydrogen; -L- is a covalent bond or methylene; and -Ar is optionally substituted aryl. The groups -X-, -R1, -R2, -R3, -R4, and -R8 are as defined herein.
(FR)
L'invention concerne un composé de polymyxine de formule (I) et des sels, des solvates et des formes protégées de celui-ci, des compositions pharmaceutiques comprenant les composés de formule (I), et l'utilisation des composés et des compositions dans des méthodes de traitement, tels que des méthodes pour le traitement d'infections microbiennes. Les composés de formule (I) sont représentés par la formule (I) dans laquelle -R15 est un groupe : formule (II) et -R16 est l'hydrogène ; -R17 est l'hydrogène ; -L- est une liaison covalente ou du méthylène ; et -Ar est un aryle éventuellement substitué. Les groupes -X-, -R1, -R2, -R3, -R4, et -R8 sont tels que définis dans la description.
Latest bibliographic data on file with the International Bureau